CBT Pharma, a CrownBio Subsidiary, Raises $9.75 Million for Oncology Drug Trials

CBT Pharmaceuticals, an innovative oncology drug subsidiary of Crown Biosciences, closed a $9.75 million Series A round led by OrbiMed Asia. Founded earlier this year, CBT received its original $5 million in startup capital from CrownBio. The company will use the Series A to conduct China-US clinical trials on two of its four oncology candidates. CrownBio, a preclinical US-China CRO/CMO focused on cancer and metabolic diseases, applied to list on the Mainboard of Taiwan's GreTai Securities Market one month ago. More details.... Share this with colleagues: // //